Financial report

Interim consolidated statement of changes in equity

For the six months ended 30 June 2021 (unaudited)

 

 

 

 

 

 

 

 

 

Attributable to equity holders of the parent

kEUR

Share capital

Share premium

Translation reserve

Treasury shares

Other capital reserves

Retained earnings

Total

 

 

 

 

 

 

 

 

Balance as at 1 January 2020

33,000

2,340

-2,694

0

0

116,770

149,416

Result for the period

 

 

 

 

 

7,831

7,831

Re-measurement losses on defined benefit plans

 

 

 

 

 

-95

-95

Currency exchange differences

 

 

-299

 

 

 

-299

Total comprehensive income

 

 

-299

0

0

7,736

7,437

 

 

 

 

 

 

 

 

Balance as at 30 June 2020

33,000

2,340

-2,993

0

0

124,506

156,853

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

kEUR

Share capital

Share premium

Translation reserve

Treasury shares

Other capital reserves

Retained earnings

Total

 

 

 

 

 

 

 

 

Balance as at 1 January 2021

33,000

2,340

-5,616

0

0

147,936

177,660

Result for the period

 

 

 

 

 

24,623

24,623

Re-measurement losses on defined benefit plans

 

 

 

 

 

2,988

2,988

Currency exchange differences

 

 

1,553

 

 

 

1,553

Total comprehensive income

0

0

1,553

0

0

27,611

29,164

 

 

 

 

 

 

 

 

Business restructuring

-33,000

33,000

 

 

 

 

0

Incorporation of PolyPeptide Group AG

273

 

 

 

 

 

273

Issue of new shares

29

182,112

 

 

 

 

182,141

IPO-related costs charged to equity

 

-4,652

 

 

 

 

-4,652

Purchase of own shares

 

 

 

-5,464

 

 

-5,464

Share-based payment

 

 

 

 

3,564

 

3,564

Transfer of own shares

 

 

 

4,094

-4,094

 

0

Repayment by Draupnir Holding B.V. related to IPO bonus

 

 

 

 

2,998

 

2,998

 

 

 

 

 

 

 

 

Balance as at 30 June 2021

302

212,800

-4,063

-1,370

2,468

175,547

385,684

The above interim consolidated statement of changes in equity should be read in conjunction with the accompanying notes.